Julie Vose, MD, MBA, on the Use of CAR T-Cell Therapy in Lymphomas


Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, about the numerous trials that read out at the meeting pertaining to CAR T-cell therapy in patients with hematologic malignancies. Vose discusses the benefit of this therapy for patients with follicular lymphoma in addition to how it may affect patients with other lymphomas.


[One category that really excites me is] the use of CAR T-cells for other types of lymphomas other than diffuse large B-cell. There were a couple of different trials that were presented [at ASCO] looking at CAR T-cells for follicular lymphoma. That has shown some follow up information, and we can see that those specific types of CAR T-cells now can be applied to other types of lymphomas and have some good outcomes. We are looking forward to applying that [technology] to other types of lymphomas, as well as other malignancies.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content